Propranolol in the Treatment of Migraine

Beta-blocking drugs that prevent cranial vasodilatation are potentially valuable in the prophylaxis of migraine. Forty-nine patients with either classic or common migraine were treated with propranolol 160 mg/day for an average of six months. The first 30 of the patients to respond well to this trea...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1974-06, Vol.2 (5921), p.699-701
Main Authors: Widerøe, Tor-Erik, Vigander, Tor
Format: Article
Language:English
Subjects:
Blood pressure
Clinical Trials as Topic
Cross over studies
Dosage
Experimentation
Female
Headache
Heart rate
Humans
Male
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - prevention & control
Migraine without Aura
Papers and Originals
Placebos
Propranolol - adverse effects
Propranolol - pharmacology
Propranolol - therapeutic use
Respiration - drug effects
Respiratory Tract Diseases - chemically induced
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beta-blocking drugs that prevent cranial vasodilatation are potentially valuable in the prophylaxis of migraine. Forty-nine patients with either classic or common migraine were treated with propranolol 160 mg/day for an average of six months. The first 30 of the patients to respond well to this treatment then participated in a double-blind cross-over trial with a placebo and propranolol. The mean frequency of headache attacks was significantly reduced by propranolol. None of the patients expressed a preference for placebo. Propranolol seems to be an effective prophylactic for common and classic migraine but the antimigraine properties of the various beta-blocking agents probably differ.
ISSN:0007-1447
0959-8138
1468-5833
DOI:10.1136/bmj.2.5921.699